Pentoxifylline
- Generic Name
- Pentoxifylline
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18N4O3
- CAS Number
- 6493-05-6
- Unique Ingredient Identifier
- SD6QCT3TSU
- Background
Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated...
- Indication
Pentoxifylline is indicated for the treatment of intermittent claudication in patients with chronic occlusive arterial disease. Pentoxifylline may improve limb function and reduce symptoms but cannot replace other therapies such as surgical bypass or removal of vascular obstructions.
- Associated Conditions
- Intermittent Claudication, Venous Leg Ulcer (VLU), Severe alcoholic liver disease
- Associated Therapies
- -
Pentoxifylline in Children With Malaria
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2010-08-27
- Target Recruit Count
- 50
- Registration Number
- NCT00133393
- Locations
- 🇰🇪
KEMRI Centre for Geographic Medicine Research, Kilifi, Kenya
Pentoxifylline in Duchenne Muscular Dystrophy
- First Posted Date
- 2005-01-31
- Last Posted Date
- 2011-10-27
- Target Recruit Count
- 17
- Registration Number
- NCT00102453
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Scottish Rite Hospital, Dallas, Texas, United States
🇺🇸Washington University at St. Louis, St. Louis, Missouri, United States
Radiation Therapy in Treating Patients With Glioblastoma
- Conditions
- First Posted Date
- 2004-04-05
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT00019058
- Locations
- 🇺🇸
Radiation Oncology Branch, Bethesda, Maryland, United States
Vitamin E and Pentoxifylline in Treating Women With Lymphedema After Radiation Therapy for Breast Cancer
- Conditions
- First Posted Date
- 2004-02-04
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Registration Number
- NCT00022204
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, England, United Kingdom
Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00001437
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Community Research Initiative of New England
- Target Recruit Count
- 60
- Registration Number
- NCT00002091
- Locations
- 🇺🇸
CRI of New England, Brookline, Massachusetts, United States
Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 54
- Registration Number
- NCT00000646
- Locations
- 🇺🇸
Case CRS, Cleveland, Ohio, United States
🇺🇸Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
Treatment of Pulmonary Sarcoidosis With Pentoxifylline
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 100
- Registration Number
- NCT00001877
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.